Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Fundacio Institut de Recerca Contra la Leucemia Josep Carreras |
| Country | Spain |
| Start Date | Jan 01, 2024 |
| End Date | Dec 31, 2027 |
| Duration | 1,460 days |
| Number of Grantees | 27 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101119927 |
The human immune system controls the efficiency to respond to infections and eliminate aberrant cells, such as cancer cells.
Immune function depends on the balanced contribution of many genes, encoding for receptors, cytokines, cell signalling molecules and transcription factors and are modulated by a wide range of environmental and epigenetic factors.
Monogenic mutations for immune-related genes, also known as Inborn Errors of Immunity (IEI), provide unique examples for understanding immune fitness.
IEI, individually considered as rare diseases, constitute a group of >400 immune disorders with a combined prevalence similar to leukemias (1/1,000-1/5,000).
For a given mutated gene, IEI patients can display a wide range of phenotypic expressivity (from asymptomatic to severely impaired) and different responses to treatments. Therefore, there is an unmet need to address the wide underlying impact of IEI. Previous EU consortia have not addressed these questions in full.
It is therefore needed a new generation of researchers, equipped with a complete set of scientific, technological and strategic skills; and a wide vision to face the outstanding challenges in the IEI field.
To this end, the IMMERGE MSCA DN combines the talent of leaders from different clinical and basic research and biotech environments to train 11 doctoral candidates.
Through our research activity and training activities, we will address key challenges in the field: 1) To assess the functional impact of IEI in different immune cell types through single cell and bulk multiomics. 2) To develop computational tools for dissecting the altered cellular pathways underlying specific IEI. 3) To genetically correct or model IEI and develop pre-clinical models.
With our strategy, IMMERGE will generate an outstanding network of professionals able to develop impactful studies that will change the field, generate tools for personalised medicine and generate awareness in the society and influence policy makers.
Universidad Pompeu Fabra; Epiqmax Gmbh; The Chancellor Masters and Scholars of the University of Cambridge; Genome Research Limited; European Molecular Biology Laboratory; Universitat Basel; Leadership Sculptor Gmbh; Albert-Ludwigs-Universitaet Freiburg; Hadassah Medical Organization; Quantitative Genomic Medicine Laboratories Sl; Universita Della Svizzera Italiana; Research Fund of the Hadassah Medical Organization (R.A); Alia Therapeutics; Universitat de Barcelona; Ospedale San Raffaele Srl; Scienseed Sl; Deutsche Selbsthilfe Angeborene Immundefekte E. V.; Universita Degli Studi Di Trento; The Hebrew University of Jerusalem; Universite D'Aix Marseille; Onechain Immunotherapeutics S.L.; Fondazione Per L'Istituto Di Ricerca in Biomedicina; Olink Proteomics Ab; Universitaetsklinikum Freiburg; Centre National de la Recherche Scientifique CNRS; Fundacio Institut de Recerca Contra la Leucemia Josep Carreras; Universita Vita-Salute San Raffaele
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant